Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments
Abstract
:1. Introduction
2. The Dopamine Hypothesis of Schizophrenia
3. Dopamine, Cognition and CIAS
4. Potential Antipsychotics or SGAs Targeting Specific Dopamine Receptors May Become the Cornerstone of CIAS Pharmacotherapy
4.1. Potential Antipsychotics
4.2. Second-Generation Antipsychotic Drugs (SGAs)
4.2.1. Clozapine
4.2.2. Risperidone
4.2.3. Aripiprazole
4.2.4. Asenapine
4.2.5. Blonanserin
4.2.6. Cariprazine
4.2.7. Brexpiprazole
5. Concluding Remarks and Future Directions
Author Contributions
Funding
Conflicts of Interest
References
- Landek-Salgado, M.A.; Faust, T.E.; Sawa, A. Molecular substrates of schizophrenia: Homeostatic signaling to connectivity. Mol. Psychiatry 2016, 21, 10–28. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Van Os, J.; Kapur, S. Schizophrenia. Lancet 2009, 374, 635–645. [Google Scholar] [CrossRef]
- Miyamoto, S.; Duncan, G.E.; Marx, C.E.; Lieberman, J.A. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005, 10, 79–104. [Google Scholar] [CrossRef] [PubMed]
- Miyamoto, S.; Miyake, N.; Jarskog, L.F.; Fleischhacker, W.W.; Lieberman, J.A. Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 2012, 17, 1206–1227. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Case, M.; Stauffer, V.L.; Ascher-Svanum, H.; Conley, R.; Kapur, S.; Kane, J.M.; Kollack-Walker, S.; Jacob, J.; Kinon, B.J. The heterogeneity of antipsychotic response in the treatment of schizophrenia. Psychol. Med. 2011, 41, 1291–1300. [Google Scholar] [CrossRef] [PubMed]
- Scheggia, D.; Mastrogiacomo, R.; Mereu, M.; Sannino, S.; Straub, R.E.; Armando, M.; Manago, F.; Guadagna, S.; Piras, F.; Zhang, F.; et al. Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment. Nat. Commun. 2018, 9, 2265. [Google Scholar] [CrossRef] [Green Version]
- Cotter, J.; Barnett, J.H.; Granger, K. The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated with Schizophrenia. Front. Psychiatry 2019, 10, 648. [Google Scholar] [CrossRef]
- Keefe, R.S.; Haig, G.M.; Marder, S.R.; Harvey, P.D.; Dunayevich, E.; Medalia, A.; Davidson, M.; Lombardo, I.; Bowie, C.R.; Buchanan, R.W.; et al. Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophr. Bull. 2016, 42, 19–33. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bowie, C.R.; Harvey, P.D. Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr. Dis. Treat. 2006, 2, 531–536. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Thornton, A.E.; Van Snellenberg, J.X.; Sepehry, A.A.; Honer, W. The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: A quantitative review. J. Psychopharmacol. 2006, 20, 335–346. [Google Scholar] [CrossRef]
- Woodward, N.D.; Purdon, S.E.; Meltzer, H.Y.; Zald, D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005, 8, 457–472. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Purdon, S.E.; Woodward, N.; Lindborg, S.R.; Stip, E. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology 2003, 169, 390–397. [Google Scholar] [CrossRef] [PubMed]
- Keefe, R.S.; Seidman, L.J.; Christensen, B.K.; Hamer, R.M.; Sharma, T.; Sitskoorn, M.M.; Rock, S.L.; Woolson, S.; Tohen, M.; Tollefson, G.D.; et al. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol. Psychiatry 2006, 59, 97–105. [Google Scholar] [CrossRef]
- Keefe, R.S.; Bilder, R.M.; Davis, S.M.; Harvey, P.D.; Palmer, B.W.; Gold, J.M.; Meltzer, H.Y.; Green, M.F.; Capuano, G.; Stroup, T.S.; et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 2007, 64, 633–647. [Google Scholar] [CrossRef]
- McCutcheon, R.A.; Abi-Dargham, A.; Howes, O.D. Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms. Trends Neurosci. 2019, 42, 205–220. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Leggio, G.M.; Bucolo, C.; Platania, C.B.; Salomone, S.; Drago, F. Current drug treatments targeting dopamine D3 receptor. Pharmacol. Ther. 2016, 165, 164–177. [Google Scholar] [CrossRef] [PubMed]
- Leggio, G.M.; Micale, V.; Le Foll, B.; Mazzola, C.; Nobrega, J.N.; Drago, F. Dopamine D3 receptor knock-out mice exhibit increased behavioral sensitivity to the anxiolytic drug diazepam. Eur. Neuropsychopharmacol. 2011, 21, 325–332. [Google Scholar] [CrossRef]
- Leggio, G.M.; Torrisi, S.A.; Castorina, A.; Platania, C.B.; Impellizzeri, A.A.; Fidilio, A.; Caraci, F.; Bucolo, C.; Drago, F.; Salomone, S. Dopamine D3 receptor-dependent changes in alpha6 GABAA subunit expression in striatum modulate anxiety-like behaviour: Responsiveness and tolerance to diazepam. Eur. Neuropsychopharmacol. 2015, 25, 1427–1436. [Google Scholar] [CrossRef]
- Torrisi, S.A.; Leggio, G.M.; Drago, F.; Salomone, S. Therapeutic Challenges of Post-traumatic Stress Disorder: Focus on the Dopaminergic System. Front. Pharmacol. 2019, 10, 404. [Google Scholar] [CrossRef] [PubMed]
- Hillarp, N.A.; Fuxe, K.; Dahlstrom, A. Demonstration and mapping of central neurons containing dopamine, noradrenaline, and 5-hydroxytryptamine and their reactions to psychopharmaca. Pharmacol. Rev. 1966, 18, 727–741. [Google Scholar]
- Carlsson, A.; Lindqvist, M. Effect of Chlorpromazine or Haloperidol on Formation of 3methoxytyramine and Normetanephrine in Mouse Brain. Acta Pharmacol. Toxicol. 1963, 20, 140–144. [Google Scholar] [CrossRef] [PubMed]
- Carlsson, A.; Lindqvist, M.; Magnusson, T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957, 180, 1200. [Google Scholar] [CrossRef]
- Davis, K.L.; Kahn, R.S.; Ko, G.; Davidson, M. Dopamine in schizophrenia: A review and reconceptualization. Am. J. Psychiatry 1991, 148, 1474–1486. [Google Scholar] [CrossRef] [PubMed]
- Howes, O.D.; Kapur, S. The dopamine hypothesis of schizophrenia: Version III—The final common pathway. Schizophr. Bull. 2009, 35, 549–562. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Howes, O.; Bose, S.; Turkheimer, F.; Valli, I.; Egerton, A.; Stahl, D.; Valmaggia, L.; Allen, P.; Murray, R.; McGuire, P. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: A PET study. Mol. Psychiatry 2011, 16, 885–886. [Google Scholar] [CrossRef] [Green Version]
- Howes, O.D.; Montgomery, A.J.; Asselin, M.C.; Murray, R.M.; Valli, I.; Tabraham, P.; Bramon-Bosch, E.; Valmaggia, L.; Johns, L.; Broome, M.; et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 2009, 66, 13–20. [Google Scholar] [CrossRef] [Green Version]
- Simpson, E.H.; Kellendonk, C.; Kandel, E. A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 2010, 65, 585–596. [Google Scholar] [CrossRef] [Green Version]
- Cools, R.; D’Esposito, M. Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol. Psychiatry 2011, 69, e113–e125. [Google Scholar] [CrossRef] [Green Version]
- Kroener, S.; Chandler, L.J.; Phillips, P.E.; Seamans, J.K. Dopamine modulates persistent synaptic activity and enhances the signal-to-noise ratio in the prefrontal cortex. PLoS ONE 2009, 4, e6507. [Google Scholar] [CrossRef] [Green Version]
- Gibbs, S.E.; D’Esposito, M. Individual capacity differences predict working memory performance and prefrontal activity following dopamine receptor stimulation. Cogn. Affect. Behav. Neurosci. 2005, 5, 212–221. [Google Scholar] [CrossRef] [Green Version]
- Kimberg, D.Y.; D’Esposito, M.; Farah, M.J. Effects of bromocriptine on human subjects depend on working memory capacity. Neuroreport 1997, 8, 3581–3585. [Google Scholar] [CrossRef] [PubMed]
- Lidow, M.S.; Koh, P.O.; Arnsten, A.F. D1 dopamine receptors in the mouse prefrontal cortex: Immunocytochemical and cognitive neuropharmacological analyses. Synapse 2003, 47, 101–108. [Google Scholar] [CrossRef]
- Zahrt, J.; Taylor, J.R.; Mathew, R.G.; Arnsten, A.F. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J. Neurosci. 1997, 17, 8528–8535. [Google Scholar] [CrossRef] [Green Version]
- De Almeida, J.; Palacios, J.M.; Mengod, G. Distribution of 5-HT and DA receptors in primate prefrontal cortex: Implications for pathophysiology and treatment. Prog. Brain Res. 2008, 172, 101–115. [Google Scholar] [CrossRef] [Green Version]
- Chudasama, Y.; Robbins, T.W. Dopaminergic modulation of visual attention and working memory in the rodent prefrontal cortex. Neuropsychopharmacology 2004, 29, 1628–1636. [Google Scholar] [CrossRef] [Green Version]
- Floresco, S.B.; Phillips, A.G. Delay-dependent modulation of memory retrieval by infusion of a dopamine D1 agonist into the rat medial prefrontal cortex. Behav. Neurosci. 2001, 115, 934–939. [Google Scholar] [CrossRef] [PubMed]
- Vijayraghavan, S.; Wang, M.; Birnbaum, S.G.; Williams, G.V.; Arnsten, A.F. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat. Neurosci. 2007, 10, 376–384. [Google Scholar] [CrossRef]
- Arnsten, A.F.; Cai, J.X.; Steere, J.C.; Goldman-Rakic, P.S. Dopamine D2 receptor mechanisms contribute to age-related cognitive decline: The effects of quinpirole on memory and motor performance in monkeys. J. Neurosci. 1995, 15, 3429–3439. [Google Scholar] [CrossRef]
- Ramaekers, J.G.; Louwerens, J.W.; Muntjewerff, N.D.; Milius, H.; de Bie, A.; Rosenzweig, P.; Patat, A.; O’Hanlon, J.F. Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J. Clin. Psychopharmacol. 1999, 19, 209–221. [Google Scholar] [CrossRef]
- Mehta, M.A.; Montgomery, A.J.; Kitamura, Y.; Grasby, P.M. Dopamine D2 receptor occupancy levels of acute sulpiride challenges that produce working memory and learning impairments in healthy volunteers. Psychopharmacology 2008, 196, 157–165. [Google Scholar] [CrossRef]
- Mehta, M.A.; Sahakian, B.J.; McKenna, P.J.; Robbins, T.W. Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson’s disease. Psychopharmacology 1999, 146, 162–174. [Google Scholar] [CrossRef]
- Watson, D.J.; Loiseau, F.; Ingallinesi, M.; Millan, M.J.; Marsden, C.A.; Fone, K.C. Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: A key role for the prefrontal cortex. Neuropsychopharmacology 2012, 37, 770–786. [Google Scholar] [CrossRef]
- Leggio, G.M.; Torrisi, S.A.; Mastrogiacomo, R.; Mauro, D.; Chisari, M.; Devroye, C.; Scheggia, D.; Nigro, M.; Geraci, F.; Pintori, N.; et al. The epistatic interaction between the dopamine D3 receptor and dysbindin-1 modulates higher-order cognitive functions in mice and humans. Mol. Psychiatry 2019, 1–14. [Google Scholar] [CrossRef]
- Sokoloff, P.; Le Foll, B. The dopamine D3 receptor, a quarter century later. Eur. J. Neurosci. 2017, 45, 2–19. [Google Scholar] [CrossRef]
- Heintz, N. Gene expression nervous system atlas (GENSAT). Nat. Neurosci. 2004, 7, 483. [Google Scholar] [CrossRef]
- Clarkson, R.L.; Liptak, A.T.; Gee, S.M.; Sohal, V.S.; Bender, K.J. D3 Receptors Regulate Excitability in a Unique Class of Prefrontal Pyramidal Cells. J. Neurosci. 2017, 37, 5846–5860. [Google Scholar] [CrossRef] [Green Version]
- Black, K.J.; Hershey, T.; Koller, J.M.; Videen, T.O.; Mintun, M.A.; Price, J.L.; Perlmutter, J.S. A possible substrate for dopamine-related changes in mood and behavior: Prefrontal and limbic effects of a D3-preferring dopamine agonist. Proc. Natl. Acad. Sci. USA 2002, 99, 17113–17118. [Google Scholar] [CrossRef] [Green Version]
- Glickstein, S.B.; Desteno, D.A.; Hof, P.R.; Schmauss, C. Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. Cereb. Cortex 2005, 15, 1016–1024. [Google Scholar] [CrossRef]
- Glickstein, S.B.; Hof, P.R.; Schmauss, C. Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits. J. Neurosci. 2002, 22, 5619–5629. [Google Scholar] [CrossRef] [Green Version]
- Nakajima, S.; Gerretsen, P.; Takeuchi, H.; Caravaggio, F.; Chow, T.; Le Foll, B.; Mulsant, B.; Pollock, B.; Graff-Guerrero, A. The potential role of dopamine D(3) receptor neurotransmission in cognition. Eur. Neuropsychopharmacol. 2013, 23, 799–813. [Google Scholar] [CrossRef] [Green Version]
- Cools, R. Dopaminergic control of the striatum for high-level cognition. Curr. Opin. Neurobiol. 2011, 21, 402–407. [Google Scholar] [CrossRef]
- Darvas, M.; Palmiter, R.D. Restriction of dopamine signaling to the dorsolateral striatum is sufficient for many cognitive behaviors. Proc. Natl. Acad. Sci. USA 2009, 106, 14664–14669. [Google Scholar] [CrossRef] [Green Version]
- Lodge, D.J.; Grace, A.A. Amphetamine activation of hippocampal drive of mesolimbic dopamine neurons: A mechanism of behavioral sensitization. J. Neurosci. 2008, 28, 7876–7882. [Google Scholar] [CrossRef] [Green Version]
- Lodge, D.J.; Grace, A.A. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol. Sci. 2011, 32, 507–513. [Google Scholar] [CrossRef] [Green Version]
- Weinberger, D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 1987, 44, 660–669. [Google Scholar] [CrossRef]
- Kahn, R.S.; Harvey, P.D.; Davidson, M.; Keefe, R.S.; Apter, S.; Neale, J.M.; Mohs, R.C.; Davis, K.L. Neuropsychological correlates of central monoamine function in chronic schizophrenia: Relationship between CSF metabolites and cognitive function. Schizophr. Res. 1994, 11, 217–224. [Google Scholar] [CrossRef]
- Tomasella, E.; Bechelli, L.; Ogando, M.B.; Mininni, C.; Di Guilmi, M.N.; De Fino, F.; Zanutto, S.; Elgoyhen, A.B.; Marin-Burgin, A.; Gelman, D.M. Deletion of dopamine D2 receptors from parvalbumin interneurons in mouse causes schizophrenia-like phenotypes. Proc. Natl. Acad. Sci. USA 2018, 115, 3476–3481. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Slifstein, M.; van de Giessen, E.; Van Snellenberg, J.; Thompson, J.L.; Narendran, R.; Gil, R.; Hackett, E.; Girgis, R.; Ojeil, N.; Moore, H.; et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: A positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry 2015, 72, 316–324. [Google Scholar] [CrossRef]
- Thompson, J.L.; Rosell, D.R.; Slifstein, M.; Girgis, R.R.; Xu, X.; Ehrlich, Y.; Kegeles, L.S.; Hazlett, E.A.; Abi-Dargham, A.; Siever, L.J. Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: A PET study with [(1)(1)C]NNC112. Psychopharmacology 2014, 231, 4231–4240. [Google Scholar] [CrossRef] [Green Version]
- Abi-Dargham, A.; Mawlawi, O.; Lombardo, I.; Gil, R.; Martinez, D.; Huang, Y.; Hwang, D.R.; Keilp, J.; Kochan, L.; Van Heertum, R.; et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci. 2002, 22, 3708–3719. [Google Scholar] [CrossRef] [Green Version]
- Abi-Dargham, A.; Xu, X.; Thompson, J.L.; Gil, R.; Kegeles, L.S.; Urban, N.; Narendran, R.; Hwang, D.R.; Laruelle, M.; Slifstein, M. Increased prefrontal cortical D(1) receptors in drug naive patients with schizophrenia: A PET study with [(1)(1)C]NNC112. J. Psychopharmacol. 2012, 26, 794–805. [Google Scholar] [CrossRef] [PubMed]
- Durstewitz, D.; Seamans, J.K. The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-o-methyltransferase genotypes and schizophrenia. Biol. Psychiatry 2008, 64, 739–749. [Google Scholar] [CrossRef]
- Papaleo, F.; Yang, F.; Garcia, S.; Chen, J.; Lu, B.; Crawley, J.N.; Weinberger, D.R. Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways. Mol. Psychiatry 2012, 17, 85–98. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fusar-Poli, P.; Howes, O.D.; Allen, P.; Broome, M.; Valli, I.; Asselin, M.C.; Grasby, P.M.; McGuire, P.K. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: A multimodal imaging study. Arch. Gen. Psychiatry 2010, 67, 683–691. [Google Scholar] [CrossRef] [Green Version]
- Krabbe, S.; Duda, J.; Schiemann, J.; Poetschke, C.; Schneider, G.; Kandel, E.R.; Liss, B.; Roeper, J.; Simpson, E.H. Increased dopamine D2 receptor activity in the striatum alters the firing pattern of dopamine neurons in the ventral tegmental area. Proc. Natl. Acad. Sci. USA 2015, 112, E1498–E1506. [Google Scholar] [CrossRef] [Green Version]
- Bach, M.E.; Simpson, E.H.; Kahn, L.; Marshall, J.J.; Kandel, E.R.; Kellendonk, C. Transient and selective overexpression of D2 receptors in the striatum causes persistent deficits in conditional associative learning. Proc. Natl. Acad. Sci. USA 2008, 105, 16027–16032. [Google Scholar] [CrossRef] [Green Version]
- Kellendonk, C.; Simpson, E.H.; Polan, H.J.; Malleret, G.; Vronskaya, S.; Winiger, V.; Moore, H.; Kandel, E.R. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 2006, 49, 603–615. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Conn, K.A.; Burne, T.H.J.; Kesby, J.P. Subcortical Dopamine and Cognition in Schizophrenia: Looking Beyond Psychosis in Preclinical Models. Front. Neurosci. 2020, 14, 542. [Google Scholar] [CrossRef]
- Arnsten, A.F.; Girgis, R.R.; Gray, D.L.; Mailman, R.B. Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia. Biol. Psychiatry 2017, 81, 67–77. [Google Scholar] [CrossRef] [Green Version]
- Mu, Q.; Johnson, K.; Morgan, P.S.; Grenesko, E.L.; Molnar, C.E.; Anderson, B.; Nahas, Z.; Kozel, F.A.; Kose, S.; Knable, M.; et al. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr. Res. 2007, 94, 332–341. [Google Scholar] [CrossRef]
- Rosell, D.R.; Zaluda, L.C.; McClure, M.M.; Perez-Rodriguez, M.M.; Strike, K.S.; Barch, D.M.; Harvey, P.D.; Girgis, R.R.; Hazlett, E.A.; Mailman, R.B.; et al. Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology 2015, 40, 446–453. [Google Scholar] [CrossRef]
- Girgis, R.R.; Van Snellenberg, J.X.; Glass, A.; Kegeles, L.S.; Thompson, J.L.; Wall, M.; Cho, R.Y.; Carter, C.S.; Slifstein, M.; Abi-Dargham, A.; et al. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. J. Psychopharmacol. 2016, 30, 428–435. [Google Scholar] [CrossRef]
- Meltzer, H.Y.; Rajagopal, L.; Matrisciano, F.; Hao, J.; Svensson, K.A.; Huang, M. The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice. Behav. Brain Res. 2019, 361, 139–150. [Google Scholar] [CrossRef]
- Kozak, R.; Kiss, T.; Dlugolenski, K.; Johnson, D.E.; Gorczyca, R.R.; Kuszpit, K.; Harvey, B.D.; Stolyar, P.; Sukoff Rizzo, S.J.; Hoffmann, W.E.; et al. Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation. Front. Pharmacol. 2020, 11, 1005. [Google Scholar] [CrossRef]
- Sun, X.; Gou, H.Y.; Li, F.; Lu, G.Y.; Song, R.; Yang, R.F.; Wu, N.; Su, R.B.; Cong, B.; Li, J. Y-QA31, a novel dopamine D3 receptor antagonist, exhibits antipsychotic-like properties in preclinical animal models of schizophrenia. Acta Pharmacol. Sin. 2016, 37, 322–333. [Google Scholar] [CrossRef] [Green Version]
- Krogmann, A.; Peters, L.; von Hardenberg, L.; Bodeker, K.; Nohles, V.B.; Correll, C.U. Keeping up with the therapeutic advances in schizophrenia: A review of novel and emerging pharmacological entities. CNS Spectr. 2019, 24, 38–69. [Google Scholar] [CrossRef]
- Bitter, I.; Lieberman, J.A.; Gaudoux, F.; Sokoloff, P.; Groc, M.; Chavda, R.; Delsol, C.; Barthe, L.; Brunner, V.; Fabre, C.; et al. Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia. Neuropsychopharmacology 2019, 44, 1917–1924. [Google Scholar] [CrossRef] [PubMed]
- Slifstein, M.; Abi-Dargham, A.; Girgis, R.R.; Suckow, R.F.; Cooper, T.B.; Divgi, C.R.; Sokoloff, P.; Leriche, L.; Carberry, P.; Oya, S.; et al. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: A PET study in healthy subjects with [(11)C]-(+)-PHNO. Psychopharmacology 2020, 237, 519–527. [Google Scholar] [CrossRef]
- Leggio, G.M.; Camillieri, G.; Platania, C.B.; Castorina, A.; Marrazzo, G.; Torrisi, S.A.; Nona, C.N.; D’Agata, V.; Nobrega, J.; Stark, H.; et al. Dopamine D3 receptor is necessary for ethanol consumption: An approach with buspirone. Neuropsychopharmacology 2014, 39, 2017–2028. [Google Scholar] [CrossRef]
- Torrisi, S.A.; Salomone, S.; Geraci, F.; Caraci, F.; Bucolo, C.; Drago, F.; Leggio, G.M. Buspirone Counteracts MK-801-Induced Schizophrenia-Like Phenotypes through Dopamine D3 Receptor Blockade. Front. Pharmacol. 2017, 8, 710. [Google Scholar] [CrossRef]
- Kardos, J.; Dobolyi, A.; Szabo, Z.; Simon, A.; Lourmet, G.; Palkovits, M.; Heja, L. Molecular Plasticity of the Nucleus Accumbens Revisited-Astrocytic Waves Shall Rise. Mol. Neurobiol. 2019, 56, 7950–7965. [Google Scholar] [CrossRef] [Green Version]
- Huang, M.; Kwon, S.; He, W.; Meltzer, H.Y. Neurochemical arguments for the use of dopamine D4 receptor stimulation to improve cognitive impairment associated with schizophrenia. Pharmacol. Biochem. Behav. 2017, 157, 16–23. [Google Scholar] [CrossRef]
- Miyauchi, M.; Neugebauer, N.M.; Meltzer, H.Y. Dopamine D4 receptor stimulation contributes to novel object recognition: Relevance to cognitive impairment in schizophrenia. J. Psychopharmacol. 2017, 31, 442–452. [Google Scholar] [CrossRef]
- Rajagopal, L.; Kwon, S.; Huang, M.; Michael, E.; Bhat, L.; Cantillon, M.; Meltzer, H.Y. RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia. Behav. Brain Res. 2017, 332, 180–199. [Google Scholar] [CrossRef]
- Lee, M.A.; Thompson, P.A.; Meltzer, H.Y. Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry 1994, 55 (Suppl. B), 82–87. [Google Scholar]
- Purdon, S.E.; Woodward, N.D.; Mintz, A.; LaBelle, A. Procedural learning improvements after six weeks of clozapine treatment. Schizophr. Res. 2002, 53, 165–166. [Google Scholar] [CrossRef]
- Regen, F.; Cosma, N.C.; Otto, L.R.; Clemens, V.; Saksone, L.; Gellrich, J.; Uesekes, B.; Ta, T.M.T.; Hahn, E.; Dettling, M.; et al. Clozapine modulates retinoid homeostasis in human brain and normalizes serum retinoic acid deficit in patients with schizophrenia. Mol. Psychiatry 2020. [Google Scholar] [CrossRef]
- Meltzer, H.Y. An overview of the mechanism of action of clozapine. J. Clin. Psychiatry 1994, 55 (Suppl. B), 47–52. [Google Scholar]
- Kawano, M.; Oshibuchi, H.; Kawano, T.; Muraoka, H.; Tsutsumi, T.; Yamada, M.; Inada, K.; Ishigooka, J. Dopamine dynamics during emotional cognitive processing: Implications of the specific actions of clozapine compared with haloperidol. Eur. J. Pharmacol. 2016, 781, 148–156. [Google Scholar] [CrossRef]
- Elsworth, J.D.; Jentsch, J.D.; Morrow, B.A.; Redmond, D.E., Jr.; Roth, R.H. Clozapine normalizes prefrontal cortex dopamine transmission in monkeys subchronically exposed to phencyclidine. Neuropsychopharmacology 2008, 33, 491–496. [Google Scholar] [CrossRef] [Green Version]
- Aoyama, Y.; Mouri, A.; Toriumi, K.; Koseki, T.; Narusawa, S.; Ikawa, N.; Mamiya, T.; Nagai, T.; Yamada, K.; Nabeshima, T. Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor. Int. J. Neuropsychopharmacol. 2014, 17, 723–737. [Google Scholar] [CrossRef] [Green Version]
- Woodward, N.D.; Jayathilake, K.; Meltzer, H.Y. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr. Res. 2007, 90, 86–96. [Google Scholar] [CrossRef]
- Leysen, J.E.; Janssen, P.M.; Megens, A.A.; Schotte, A. Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry 1994, 55 (Suppl. 5–12). [Google Scholar]
- Casey, A.B.; Canal, C.E. Classics in Chemical Neuroscience: Aripiprazole. ACS Chem. Neurosci. 2017, 8, 1135–1146. [Google Scholar] [CrossRef]
- Fejgin, K.; Safonov, S.; Palsson, E.; Wass, C.; Engel, J.A.; Svensson, L.; Klamer, D. The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology 2007, 191, 377–385. [Google Scholar] [CrossRef] [PubMed]
- Braff, D.L. Information processing and attention dysfunctions in schizophrenia. Schizophr. Bull. 1993, 19, 233–259. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tuplin, E.W.; Holahan, M.R. Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity. Curr. Neuropharmacol. 2017, 15, 1192–1207. [Google Scholar] [CrossRef] [Green Version]
- Nagai, T.; Murai, R.; Matsui, K.; Kamei, H.; Noda, Y.; Furukawa, H.; Nabeshima, T. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology 2009, 202, 315–328. [Google Scholar] [CrossRef]
- Kim, E.; Howes, O.D.; Turkheimer, F.E.; Kim, B.H.; Jeong, J.M.; Kim, J.W.; Lee, J.S.; Jang, I.J.; Shin, S.G.; Kapur, S.; et al. The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory: A dual [(11)C]raclopride and [(18) F]FDG imaging study with aripiprazole. Psychopharmacology 2013, 227, 221–229. [Google Scholar] [CrossRef] [PubMed]
- Shin, S.; Kim, S.; Seo, S.; Lee, J.S.; Howes, O.D.; Kim, E.; Kwon, J.S. The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: A [(11)C]-raclopride PET study with aripiprazole. Transl. Psychiatry 2018, 8, 87. [Google Scholar] [CrossRef]
- Shahid, M.; Walker, G.B.; Zorn, S.H.; Wong, E.H. Asenapine: A novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol. 2009, 23, 65–73. [Google Scholar] [CrossRef]
- Snigdha, S.; Idris, N.; Grayson, B.; Shahid, M.; Neill, J.C. Asenapine improves phencyclidine-induced object recognition deficits in the rat: Evidence for engagement of a dopamine D1 receptor mechanism. Psychopharmacology 2011, 214, 843–853. [Google Scholar] [CrossRef]
- Jardemark, K.; Marcus, M.M.; Shahid, M.; Svensson, T.H. Effects of asenapine on prefrontal N-methyl-D-aspartate receptor-mediated transmission: Involvement of dopamine D1 receptors. Synapse 2010, 64, 870–874. [Google Scholar] [CrossRef] [PubMed]
- Ohoyama, K.; Yamamura, S.; Hamaguchi, T.; Nakagawa, M.; Motomura, E.; Shiroyama, T.; Tanii, H.; Okada, M. Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex. Eur. J. Pharmacol. 2011, 653, 47–57. [Google Scholar] [CrossRef]
- Tadori, Y.; Forbes, R.A.; McQuade, R.D.; Kikuchi, T. Functional potencies of dopamine agonists and antagonists at human dopamine D(2) and D(3) receptors. Eur. J. Pharmacol. 2011, 666, 43–52. [Google Scholar] [CrossRef] [PubMed]
- Hida, H.; Mouri, A.; Mori, K.; Matsumoto, Y.; Seki, T.; Taniguchi, M.; Yamada, K.; Iwamoto, K.; Ozaki, N.; Nabeshima, T.; et al. Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: The complex mechanism of blonanserin action involving D(3)-5-HT(2)A and D(1)-NMDA receptors in the mPFC. Neuropsychopharmacology 2015, 40, 601–613. [Google Scholar] [CrossRef]
- Huang, M.; Kwon, S.; Oyamada, Y.; Rajagopal, L.; Miyauchi, M.; Meltzer, H.Y. Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement. Pharmacol. Biochem. Behav. 2015, 138, 49–57. [Google Scholar] [CrossRef]
- Kotani, M.; Enomoto, T.; Murai, T.; Nakako, T.; Iwamura, Y.; Kiyoshi, A.; Matsumoto, K.; Matsumoto, A.; Ikejiri, M.; Nakayama, T.; et al. The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets. Behav. Brain Res. 2016, 305, 212–217. [Google Scholar] [CrossRef] [PubMed]
- Calabrese, F.; Tarazi, F.I.; Racagni, G.; Riva, M.A. The role of dopamine D3 receptors in the mechanism of action of cariprazine. CNS Spectr. 2020, 25, 345–351. [Google Scholar] [CrossRef]
- Pich, E.M.; Collo, G. Pharmacological targeting of dopamine D3 receptors: Possible clinical applications of selective drugs. Eur. Neuropsychopharmacol. 2015, 25, 1437–1447. [Google Scholar] [CrossRef]
- Zimnisky, R.; Chang, G.; Gyertyan, I.; Kiss, B.; Adham, N.; Schmauss, C. Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology 2013, 226, 91–100. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Neill, J.C.; Grayson, B.; Kiss, B.; Gyertyan, I.; Ferguson, P.; Adham, N. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. Eur. Neuropsychopharmacol. 2016, 26, 3–14. [Google Scholar] [CrossRef]
- Watson, D.J.G.; King, M.V.; Gyertyan, I.; Kiss, B.; Adham, N.; Fone, K.C.F. The dopamine D(3)-preferring D(2)/D(3) dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. Eur. Neuropsychopharmacol. 2016, 26, 208–224. [Google Scholar] [CrossRef]
- Maeda, K.; Lerdrup, L.; Sugino, H.; Akazawa, H.; Amada, N.; McQuade, R.D.; Stensbol, T.B.; Bundgaard, C.; Arnt, J.; Kikuchi, T. Brexpiprazole II: Antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J. Pharmacol. Exp. Ther. 2014, 350, 605–614. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bjorkholm, C.; Marcus, M.M.; Konradsson-Geuken, A.; Jardemark, K.; Svensson, T.H. The novel antipsychotic drug brexpiprazole, alone and in combination with escitalopram, facilitates prefrontal glutamatergic transmission via a dopamine D1 receptor-dependent mechanism. Eur. Neuropsychopharmacol. 2017, 27, 411–417. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Torrisi, S.A.; Laudani, S.; Contarini, G.; De Luca, A.; Geraci, F.; Managò, F.; Papaleo, F.; Salomone, S.; Drago, F.; Leggio, G.M. Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments. Pharmaceuticals 2020, 13, 365. https://doi.org/10.3390/ph13110365
Torrisi SA, Laudani S, Contarini G, De Luca A, Geraci F, Managò F, Papaleo F, Salomone S, Drago F, Leggio GM. Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments. Pharmaceuticals. 2020; 13(11):365. https://doi.org/10.3390/ph13110365
Chicago/Turabian StyleTorrisi, Sebastiano Alfio, Samuele Laudani, Gabriella Contarini, Angelina De Luca, Federica Geraci, Francesca Managò, Francesco Papaleo, Salvatore Salomone, Filippo Drago, and Gian Marco Leggio. 2020. "Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments" Pharmaceuticals 13, no. 11: 365. https://doi.org/10.3390/ph13110365